RRML - An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- March 2019 -
 
To translate or not to transla... 14
Assessment of Serum Ischemia-m... 7
Ischemia modified albumin in e... 6
Comparison of TB Values Measur... 6
Arylesterase activity of Parao... 5
Cardiac mesenchymal hamartoma ... 5
miR-190, CDK1, MCM10 and NDC80... 5
An experimental in-vitro study... 5
Do we really need genetic test... 5
IL-6 gene polymorphisms and se... 4

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 27(1)/2019 DOI:10.2478/rrlm-2019-0003
XML
TXT

Research article

An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid

Muhammet Murat Celik, Nizami Duran

Correspondence should be addressed to: Nizami Duran

Abstract:

Aim: The aim of this study was to investigate the in-vitro efficacy of Glycyrrhetinic acid against Helicobacter pylori (H. pylori) strains, as compared with conventional antibacterial agents. Methods: A total of 41 H. pylori isolates were used, 6 of which were of standard strains (NCTC 1637), 8 of which were drug-sensitive, and 27 were resistant to drugs isolates. Clarithromycin and metronidazole resistance in all strains of H. pylori were determined by the Epsilometer test (E-test) method. MIC study was performed by using microdilution broth method. Results: Glycyrrhetinic acid was found to be effective against H. pylori NCTC 1637 in doses of 12.0±4.38 µg/mL, while the MIC value of clinical H. pylori isolates susceptible to antimicrobials was 20.8±10.11 µg/ml. It was found that the MIC values for antimicrobial-sensitive clinical H. pylori isolates was higher when compared with H. pylori NCTC 1637 strains. The MIC values of the standard antimicrobial agents against drug-resistant H. pylori strains were higher than H. pylori NCTC 1637 strains and drug-sensitive H. pylori strains. The MIC value was found to be 14.22±7.77 µg/ml for metronidazole, 3.89±1.90 µg/ml for clarithromycin, 2.33±1.0 µg/ml for amoxicillin, 2.44±0.88 µg/ml for levofloxacin and 4.89±2.47 µg/ml for tetracycline, whereas the MIC value of Glycyrrhetinic acid was 26.67±8.0 µg/ml in metronidazole-resistant H. pylori isolates. Besides, MIC values of the antimicrobials and 18ß-Glycyrrhetinic acid among the strains resistant to clarithromycin were as follows: 3.25±2.12 µg/ml for metronidazole, 9.71±4.54 µg/ml for clarithromycin, 2.06±1.32 µg/ml for amoxicillin, 3.88±4.22 µg/ml for levofloaxacin and 3.25±1.04 µg/mL for tetracycline and 22.0±11.11 µg/ml for Glycyrrhetinic acid. Conclusion: Glycyrrhetinic acid had significant antimicrobial activity against H. pylori strains. Although further in-vivo studies are needed on antimicrobial activity of Glycyrrhetinic acid, increased resistance to drugs currently used in treatment suggests that Glycyrrhetinic acid may be a potential agent for the treatment of H. pylori.

Keywords: Glycyrrhetinic acid, Helicobacter pylori, drug, resistance, metronidazole, clarithromycin

Received: 17.6.2018
Accepted: 3.11.2018
Published: 6.1.2019

 
  PDF Download full text PDF
(461 KB)
     
 
How to cite
Celik MM, Duran N. An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid. Rev Romana Med Lab. 2019;27(1):63-71. DOI:10.2478/rrlm-2019-0003